2C-B-DragonFLY, also known as 2C-B-DFLY, is a psychedelic drug of the phenethylamine, 2C, and FLY families. It is the "DragonFLY" (benzodifuran) analogue of 2C-B and 2C-B-FLY as well as the phenethylamine (ñ-desmethyl) analogue of Bromo-DragonFLY (DOB-DFLY).
The properties and effects of 2C-B-DragonFLY in humans do not appear to be known.
2C-B-DragonFLY's predicted affinity (K<sub>i</sub>) for the serotonin 5-HT<sub>2A</sub> receptor has been reported to be 26nM. It produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. 2C-B-DragonFLY is about 2.2-fold more potent than 2C-B and about 1.7-fold more potent than 2C-B-FLY in terms of this effect. On the other hand, it is about 5-fold less potent than Bromo-DragonFLY in producing the head-twitch response in rodents. These findings demonstrate the importance of the fully aromatic benzodifuran ring system for optimal serotonin 5-HT<sub>2A</sub> receptor interaction, though 2C-B-DragonFLY is still considerably less potent than Bromo-DragonFLY.
Analogues of 2C-B-DragonFLY include 2C-B, 2C-B-FLY, 2C-B-ButterFLY, and Bromo-DragonFLY (DOB-DFLY), among others.
2C-B-DragonFLY was first described in the scientific literature by 1999. Subsequently, its pharmacology was described by Adam Halberstadt and colleagues in 2019.
2C-B-DragonFLY is a controlled substance in Canada under phenethylamine blanket-ban language.
2C-B-DragonFLY is not an explicitly controlled substance in the United States.